Malaysia

Population 2017: 32 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2017</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>1.3 (1.1–1.4)</td>
<td>4.3 (3.5–4.5)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.3 (0.22–0.38)</td>
<td>0.93 (0.69–1.2)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>29 (25–34)</td>
<td>93 (79–107)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>1.8 (1.5–2.1)</td>
<td>5.7 (4.8–6.6)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>0.57 (0.42–0.73)</td>
<td>1.8 (1.3–2.3)</td>
</tr>
</tbody>
</table>

Estimated TB burden by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>2.0 (1.9–2)</td>
<td>18 (1.7–1.9)</td>
<td>22 (2.0–2.0)</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>9.2 (8.4–9.9)</td>
<td>16 (15–16)</td>
<td>10 (9.8–10.2)</td>
</tr>
<tr>
<td>Total</td>
<td>11 (10–12)</td>
<td>18 (16–20)</td>
<td>29 (25–34)</td>
</tr>
</tbody>
</table>

TB case notifications, 2017

- % tested with rapid diagnostics at time of diagnosis
  - % with known HIV status: 87%
  - % pulmonary: 85%
  - % bacteriologically confirmed among pulmonary: 74%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2017: 87% (75–100)

TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2017: 0.05 (0.04–0.06)

TB/HIV care in new and relapse TB patients, 2017

- % on antiretroviral therapy: 949 (70%)

Drug-resistant TB care, 2017

- Estimated MDR/RR-TB cases among notified pulmonary TB cases: 370 (290–460)
- Estimated % of TB cases with MDR/RR-TB: 1.5% (1.2–1.9), 3.1% (1.3–5.9)
- % notified tested for rifampicin resistance: 47%
- % with known HIV status who are HIV-positive: 1356 (6%)
- % with unknown previous TB treatment history: 11 (10–12)

Laboratory-confirmed cases

MDR/RR-TB: 352, XDR-TB: 1

Patients started on treatment ****

MDR/RR-TB: 97, XDR-TB: 0

Treatment success rate and cohort size

- New and relapse cases registered in 2016: 80% (25,005)
- Previously treated cases, excluding relapse, registered in 2016: 50% (736)
- HIV-positive TB cases registered in 2016: 56% (1,406)
- MDR/RR-TB cases started on second-line treatment in 2015: 41% (85)
- XDR-TB cases started on second-line treatment in 2015: 0

TB preventive treatment, 2017

% of HIV-positive people (newly enrolled in care) on preventive treatment: 79%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 100% (87–100)

TB financing, 2018

- National TB budget (US$ millions): 16
- Funding source: 100% domestic, international, 0% unfunded

*Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2018-11-16
Data: www.who.int/tb/data